These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25382021)

  • 41. Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD.
    Med Lett Drugs Ther; 2014 Apr; 56(1440):30-1. PubMed ID: 24736248
    [No Abstract]   [Full Text] [Related]  

  • 42. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
    [No Abstract]   [Full Text] [Related]  

  • 43. Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
    Marshall J; Sharma A; Darken P; Ouwens M; Singh B; Tansey-Dwyer D
    Adv Ther; 2023 May; 40(5):2549-2555. PubMed ID: 37004641
    [No Abstract]   [Full Text] [Related]  

  • 44. [Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease].
    Bolotova EV; Dudnikova AV; Shulzhenko LV
    Ter Arkh; 2022 Mar; 94(3):396-400. PubMed ID: 36286904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial.
    Bjermer L; Boucot IH; Maltais F; Kerwin EM; Naya IP; Tombs L; Jones PW; Compton C; Lipson DA; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1939-1956. PubMed ID: 34234425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
    Antohe I; Antoniu SA; Gavrilovici C
    Expert Opin Pharmacother; 2018 Feb; 19(3):287-289. PubMed ID: 29271268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study.
    Pelaia C; Ferrante Bannera A; Rotundo FL; Tropea FG; Armentaro G; Maglio A; Sciacqua A; Vatrella A; Pelaia G
    Int J Chron Obstruct Pulmon Dis; 2023; 18():995-1002. PubMed ID: 37260547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. COPD exacerbation costs in the IMPACT study: a within-trial analysis.
    Bogart MR; Hopson SD; Shih HC; Stanford RH; Coutinho AD
    Am J Manag Care; 2020 May; 26(5):e150-e154. PubMed ID: 32436683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [IMPACT study in COPD].
    Corhay JL
    Rev Med Liege; 2019 Jan; 74(1):54-60. PubMed ID: 30680975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Mehta R; Green M; Patel B; Wagg J
    J Pharmacokinet Pharmacodyn; 2016 Apr; 43(2):153-64. PubMed ID: 26739997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.
    Riley JH; Tabberer M; Richard N; Donald A; Church A; Harris SS
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1873-80. PubMed ID: 27578968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease.
    Gong Y; Lin C; Jin Y; Chen R
    Can Respir J; 2022; 2022():2878648. PubMed ID: 36060827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
    Hu C; Jia J; Dong K; Luo L; Wu K; Mehta R; Peng J; Ren Y; Gross A; Yu H
    PLoS One; 2015; 10(3):e0121264. PubMed ID: 25816315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
    Goyal N; Beerahee M; Kalberg C; Church A; Kilbride S; Mehta R
    Clin Pharmacokinet; 2014 Jul; 53(7):637-48. PubMed ID: 24756395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate.
    Hussar DA; Dharsi N
    J Am Pharm Assoc (2003); 2014; 54(4):450-2, 454-5. PubMed ID: 25063267
    [No Abstract]   [Full Text] [Related]  

  • 58. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
    Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Umeclidinium for the treatment of chronic obstructive pulmonary disease.
    Segreti A; Calzetta L; Rogliani P; Cazzola M
    Expert Rev Respir Med; 2014 Dec; 8(6):665-71. PubMed ID: 25312239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.